Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model

Autor: Erik Hooijberg, Pc, Den Berk, Jj, Sein, Wijdenes J, Aa, Hart, Rw, Boer, Cj, Melief, Hekman A

Publikováno v: Europe PubMed Central

We used a nude mouse xenograft tumor model to compare the efficacy of unconjugated CD19 and CD20 mAbs (IgG2a subclass) in mediating antilymphoma effects. Treatment with the CD20 mAbs NKI-B20 and BCA-B20 resulted in a drastic decrease in tumor take ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7bdab3a581e10283ade5cdb0eac8a642
https://pubmed.ncbi.nlm.nih.gov/7531616

Role of LFA-1 and VLA-4 in the adhesion of cloned normal and LFA-1 (CD11/CD18)-deficient T cells to cultured endothelial cells. Indication for a new adhesion pathway

Autor: Cj, Vennegoor, van de Wiel-van Kemenade E, Rj, Huijbens, Sanchez-Madrid F, Cj, Melief, Cg, Figdor

Publikováno v: Europe PubMed Central

Patients with the leukocyte adhesion deficiency (LAD) syndrome have a genetic defect in the common beta 2-chain (CD18) of the leukocyte integrins. This defect can result in the absence of cell surface expression of all three members of the leukocyte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::9bf53d15392cc2ab3947ac7cb788fab1
https://pubmed.ncbi.nlm.nih.gov/1371131

Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes

Autor: Alice Sijts, Ossendorp F, Ea, Mengedé, Pj, Den Elsen, Cj, Melief

Publikováno v: Europe PubMed Central

H-2b mice are immunologic responders to the tumorigenic MCF1233 murine leukemia virus (MuLV), an AKV-related virus derived from endogenous C57BL MuLV. We have identified an immunodominant CTL epitope that is expressed on MCF1233 MuLV-induced lymphoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f07f9d26a51f22412e939d1279e0e447
http://europepmc.org/abstract/med/8254184

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.

Autor: Massarelli E; Department of Medical Oncology, City of Hope National Medical Center, Duarte, California., William W; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Johnson F; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Kies M; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Ferrarotto R; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Guo M; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston., Feng L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston., Lee JJ; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston., Tran H; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Kim YU; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Haymaker C; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston., Bernatchez C; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Curran M; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston., Zecchini Barrese T; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston., Rodriguez Canales J; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston., Wistuba I; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston., Li L; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston., Wang J; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston., van der Burg SH; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Melief CJ; Department of Immunohematology and Blood Tranfusion, Leiden University Medical Center, Leiden, the Netherlands.; ISA Pharmaceuticals, Leiden, the Netherlands., Glisson B; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.

Publikováno v: JAMA oncology [JAMA Oncol] 2019 Jan 01; Vol. 5 (1), pp. 67-73.

Control of immune escaped human papilloma virus is regained after therapeutic vaccination.

Autor: Ma W; Department of Medical Oncology, Building 1, C7-141, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands., Melief CJ; ISA Pharmaceuticals, J.H. Oortweg 19, 2333 CH, Leiden, The Netherlands., van der Burg SH; Department of Medical Oncology, Building 1, C7-141, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: shvdburg@lumc.nl.

Publikováno v: Current opinion in virology [Curr Opin Virol] 2017 Apr; Vol. 23, pp. 16-22. Date of Electronic Publication: 2017 Mar 07.